The current situation of cancer morbidity and mortality in the light of the National Cancer Registry, Hungary.
Prostate ; — Molecular pathology of prostate cancer. Molecular subtypes and perspectives prostate cancer treatments 2021 targeted therapies in prostate cancer.
Molecular underpinnings of systemic treatment resistance in metastatic castration-resistant prostate cancer. Integrative clinical genomics of advanced prostate cancer. Cell ; — Germline and somatic mutations in prostate cancer for the clinician.
J Natl Compr Canc Netw. Germline genetic testing in prostate cancer — further enrichment in variant histologies?
Prostate Cancer Radiation Fiducial Marker and SpaceOAR Gel Procedure ABS Virtual Reality (360 VR)
Oncoscience ; 5: 62— Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med. Eur Urol.
Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol. J Clin Oncol ; — Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer.
The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer. Cancer ; — Medical treatment options in BRCA-associated cancers.
Genomic analysis of three metastatic prostate cancer patients with exceptional responses to carboplatin indicating different types of DNA repair deficiency. Prostate Cancer.
DOI: Bevezetés: Az utóbbi években az oligometastaticus prosztatadaganatok kezelése során a szisztémás kezelés mellett egyre gyakrabban végzik a primer tumor lokális kezelését is.
Version 2. Mutations in BRCA2 and taxane resistance in prostate cancer.
University of Kansas Medical Center Rövid összefoglaló The primary objective of this study is to demonstrate that ultra-hypofractionation of prostate cancer does not increase urinary toxicity as defined by the EPIC GU domain patient reported outcome. Részletes leírás This is a pilot clinical trial looking at 2 fraction SBRT radiation therapy as an alternative to standard of care. Data does not yet exist for the safety and efficacy of this regimen. However, the feasibility of ultra-short radiation therapy treatments has already been demonstrated in an analogous treatment using high-dose rate HDR brachytherapy.